January 15, 2020

Mark A. Goldsmith
Chief Executive Officer
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, CA 94063

       Re: Revolution Medicines, Inc.
           Amendment No. 2 to Draft Registration Statement on Form S-1
           Submitted January 10, 2020
           CIK No. 0001628171

Dear Dr. Goldsmith:

      We have reviewed your amended draft registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in our
November 5, 2019 letter.

Amendment No. 2 to Draft Registration Statement on Form S-1

Prospectus Summary
Our product candidates, page 3

1.     We note your disclosure on page 4 that you have entered into an
agreement with Amgen
       to evaluate the combination of RMC-4630 and Amgen's KRASG12C (OFF)
       AMG 510 in a Phase 1b trial that will be conducted by Amgen. Please
describe the
       material terms of this agreement and file it as an exhibit to your
registration statement.
 Mark A. Goldsmith
Revolution Medicines, Inc.
January 15, 2020
Page 2
Management's discussion and analysis of financial condition and results of
Comparison of the Results of Operations for the nine months ended September 30,
2018 and
2019, page 95

2.       We note your 287%, 95% and 48% increases in collaboration revenue,
research and
         development expense, and general and administrative expense during the
nine months
         ended September 30, 2019 compared to the same period in 2018. Please
expand each of
         these disclosures to explain whether you believe any of these
increases represent a trend to
         continue in future periods. See Item 303(b) of Regulation S-K,
including Instruction 3

Compensation committee interlocks and insider participation, page 178

3.       Please update to include disclosure regarding the last completed
fiscal year.
Exhibits and financial statement schedules, page II-3

4.       Please file as exhibits to your registration statement the forms of
the new employment
         agreements you intend to enter into with your named executive officers
in connection with
         this offering.
       You may contact Bonnie Baynes at 202-551-4924 or Lisa Vanjoske at
202-551-3614 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Sonia Bednarowski at 202-551-3666 or Dietrich King at 202-551-8071 with
any other

FirstName LastNameMark A. Goldsmith                            Sincerely,
Comapany NameRevolution Medicines, Inc.
                                                               Division of
Corporation Finance
January 15, 2020 Page 2                                        Office of Life
FirstName LastName